Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
TransCode Therapeutics Inc. (RNAZ) had Weighted-Average Shares Outstanding (Diluted) of 0.83M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-4.28M |
|
-- |
|
-- |
|
$4.22M |
|
$-4.22M |
|
$-0.06M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.22M |
|
$-4.21M |
|
0.83M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
0.83M |
$-5.13 |
|
$-5.13 |
|
| Balance Sheet Financials | |
$8.24M |
|
$0.02M |
|
$0.02M |
|
$8.27M |
|
$1.56M |
|
-- |
|
$0.55M |
|
$2.12M |
|
$6.15M |
|
$6.15M |
|
$6.15M |
|
0.83M |
|
| Cash Flow Statement Financials | |
$-7.29M |
|
-- |
|
$8.85M |
|
$5.81M |
|
$7.37M |
|
$1.56M |
|
$0.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.27 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-69.56% |
|
-69.56% |
|
-51.73% |
|
-69.56% |
|
$7.37 |
|
$-8.75 |
|
$-8.75 |
|